Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3):198-206

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti

 

ORIGINAL ARTICLES   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 September;48(3):198-206

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancre-atic carcinoma

Li S. 1, Peck-Radosavljevic M. 2, Kienast O. 1, Preitfellner J. 1, Havlik E. 3, Schima W. 4, Traub-Weidinger T. 1, Graf S. 5, Beheshti M. 1, Schmid M. 2, Angelberger P. 6, Dudczak R. 1

1 Department of Nuclear Medicine Medical University of Vienna, Vienna, Austria 2 Department of Internal Medicine IV Division of Gastroenterology and Hepatology Medical University of Vienna, Vienna, Austria 3 Institute for Biomedical Technology and Physik Medical University of Vienna, Vienna, Austria 4 Department of Radiology, Medical University of Vienna, Vienna, Austria 5 Department of Internal Medicine II, Division of Cardiology Medical University of Vienna, Vienna, Austria, 6 Austrian Research Center, Seibersdorf, Austria


PDF


Aim. Imaging ­with radio­lab­elled vas­cu­lar endo­the­lial ­growth fac­tor (­VEGF) has ­been devel­oped for the local­isa­tion and diag­no­sis of a varie­ty of ­human sol­id ­tumors includ­ing gas­troin­tes­ti­nal ­tumors.
Methods. In ­this ­study we inves­ti­gat­ed the bio­dis­tri-
b­u­tion, safe­ty and ­absorbed ­dose of ­iodine-123 radio­lab­elled ­VEGF165 (123I-­VEGF165) in 9 ­patients ­with pan­creat­ic car­ci­no­ma. Following intra­ve­nous admin­is­tra­tion of 123I-­VEGF165 (189±17 MBq; <130 ­pmole (<5 μg) ­VEGF165 per ­patient), sequen­tial imag­es ­were record­ed dur­ing the ­initial 30 min ­PI. Serial ­whole-­body imag­es ­were ­acquired in ante­ri­or and pos­te­ri­or ­views at var­i­ous ­time ­points. All ­patients under­went sin­gle-pho­ton emis­sion tomog­ra­phy (­SPET) imag­ing. Dosimetry cal­cu­la­tions ­were per­formed on the ­basis of γ cam­e­ra ­data. Estimates of radi­a­tion ­absorbed ­dose ­were cal­cu­lat­ed ­using the MIR­DOSE 3 pro­gram.
Results. The high­est ­absorbed ­organ dos­es ­were ­found to be thy­roid (0.058±0.004 mGy/MBq), ­spleen (0.046± 0.017 mGy/MBq), uri­nary blad­der (0.04±0.02 mGy/MBq), ­lungs (0.034±0.009 mGy/MBq) and kid­neys (0.033±0.005 mGy/MBq). The effec­tive ­dose was esti­mat­ed to be 0.017±0.002 mSv/MBq. A major­ity of pri­mary pan­creat­ic ­tumors and ­their metas­ta­ses ­were vis­u­al­ized by 123I-­VEGF165 ­scan.
Conclusion. In ­vitro bind­ing ­results con­firmed spe­cif­ic bind­ing of 123I-­VEGF165 to pan­creat­ic ­tumor ­cells and tis­sues. 123I-­VEGF165 ­shows favor­able dosim­e­try and is a ­safe radio­phar­ma­ceu­ti­cal ­that may be of poten­tial val­ue for the imag­ing of ­VEGF recep­tor stat­us in ­vivo.

inizio pagina